Home > Healthcare > Medical Devices > Diagnostic Devices > Hepatitis E Diagnostic Tests Market

Hepatitis E Diagnostic Tests Market Share

Report ID: GMI10834
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Hepatitis E Diagnostic Tests Market Share

The market is highly competitive, with a mix of major global players and numerous smaller to medium-sized companies. Leading firms prioritize innovation by making significant investments in research and development to enhance product performance and comply with evolving regulatory standards. Strategic partnerships, acquisitions, and mergers play a crucial role in strengthening market positions and expanding global presence.

Hepatitis E Diagnostic Tests Market Companies

Some of the eminent market participants operating in the hepatitis E diagnostic tests industry include:

altona Diagnostics GmbH
CTK Biotech, Inc.
Dia.Pro Diagnostic Bioprobes s.r.l
DiaSorin S.p.A.
ELITechGroup (Bruker company)
F. Hoffmann-La Roche Ltd
Fortress Diagnostics
Genscript Biotech Corporation
Guangzhou Wondfo Biotech Co., Ltd.
Medsource Ozone Biomedicals Pvt. Ltd.
MIKROGEN GmbH
MP Biomedicals
Primer Design
Wantai BioPharm

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Hepatitis E diagnostic tests market size was valued at USD 60 million in 2023 and is estimated to grow at 4.3% CAGR from 2024 to 2032 due to rising awareness and screening programs.

The hospitals segment in the market accounted for USD 25.7 million in 2023 as they often serve as central hubs for patient care.

The U.S. hepatitis E diagnostic tests market is projected to reach USD 34.2 million by 2032 led by advances in diagnostic technologies and the rise of point-of-care testing.

altona Diagnostics GmbH, CTK Biotech, Inc., Dia.Pro Diagnostic Bioprobes s.r.l, DiaSorin S.p.A., ELITechGroup (Bruker company), F. Hoffmann-La Roche Ltd, Fortress Diagnostics, Genscript Biotech Corporation, and Guangzhou Wondfo Biotech Co., Ltd.